Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update – Nasdaq
|
Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update
Nasdaq "In 2016, we significantly broadened our scientific platform with CRISPR/Cpf1 and advanced forms of CRISPR/Cas9, demonstrated proof-of-editing in vivo for our most advanced program in LCA10, and expanded our leadership team with the addition of our … |
